Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.
The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.
In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.
Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.
For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.
Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.
Tandem Diabetes Care and Dexcom have announced that the t:slim X2 insulin pump with Dexcom G7 CGM compatibility has been authorized for sale by Health Canada. This integration makes it the only Automated Insulin Delivery (AID) system in Canada compatible with both Dexcom G7 and G6 CGM technologies. The updated software is expected to be commercially available this fall, with existing users receiving a free remote update.
Key features of the integration include:
- Dexcom G7's smaller, all-in-one sensor and transmitter
- 30-minute sensor warmup time
- 12-hour grace period for sensor replacement
- Increased connectivity with digital health apps
The t:slim X2 pump with Control-IQ technology is rated as the #1 AID system in Canada, offering customizable profiles and various infusion set options.
Tandem Diabetes Care (NASDAQ: TNDM) will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market closes. The company will hold a conference call and webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on the same day to discuss the financial and operating results. The live webcast will be available on Tandem Diabetes Care's Investor Center website. An archived version of the webcast will be accessible for 30 days post-event.
Tandem Diabetes Care (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has appointed Jean-Claude 'JC' Kyrillos as the new Executive Vice President and Chief Operating Officer, effective June 21, 2024. Kyrillos brings over 20 years of global executive leadership experience in medical devices, digital health, and healthcare management.
Kyrillos previously held key roles at Envista Holdings, Qualcomm Life, Becton Dickinson, and ResMed. He has also served as an independent board director at the San Diego Blood Bank. Tandem's CEO, John Sheridan, highlighted Kyrillos' extensive technical, operational, and leadership skills.
Kyrillos expressed enthusiasm for joining Tandem, focusing on expanding global operations and delivering profitable growth while advancing their mission to improve lives through innovative insulin delivery technologies.
Tandem Diabetes Care (NASDAQ: TNDM) is set to present early user insights on its new Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions from June 21-24 in Orlando, Florida.
The Product Theater session, scheduled for June 22, will feature presentations by key medical experts on the benefits of Tandem Mobi, the world's smallest durable Automated Insulin Delivery (AID) system, and its Control-IQ algorithm. The presenters will discuss the system's unique wearability and potential to improve patient outcomes.
Additional poster presentations will cover various studies on the t:slim X2 insulin pump with Control-IQ Technology and the Tandem t:connect mobile application.
Tandem Diabetes Care will also exhibit at Booth #1621, showcasing the Tandem Mobi and t:slim X2 systems, both compatible with multiple Continuous Glucose Monitors (CGMs).
Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.
This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.
Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.
This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.
Tandem Diabetes Care (NASDAQ: TNDM) will present a company update at the Jefferies Global Healthcare Conference on June 6, 2024, at 8:00 am Eastern Time (5:00 am Pacific Time).
The update will be webcast live, with an archive available for 30 days on the company’s Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported a 13% increase in worldwide GAAP sales to $191.7 million and a 12% increase in non-GAAP sales to $192.8 million for the first quarter of 2024. The company launched Tandem Mobi with Dexcom G6 CGM sensor integration and t:slim X2 with Abbott Freestyle Libre 2 Plus CGM sensor integration in the US, among other initiatives. The increase in pump shipments and financial results showcased positive growth. However, the company reported a net loss for the quarter.
Tandem Diabetes Care, Inc. (TNDM) will present at investor conferences on May 15 and May 29, 2024, providing company updates. The presentations will be webcast live and archived for 30 days.
FAQ
What is the current stock price of Tandem Diabetes Care (TNDM)?
What is the market cap of Tandem Diabetes Care (TNDM)?
What is Tandem Diabetes Care, Inc. known for?
Where is Tandem Diabetes Care, Inc. located?
What are the main products of Tandem Diabetes Care, Inc.?
How do the t:slim X2™ insulin pump updates work?
What percentage of Tandem Diabetes Care's revenue comes from the U.S.?
Does Tandem Diabetes Care offer customer support?
What recent products has Tandem Diabetes Care introduced?
What materials are required to replace in Tandem's insulin pumps?
What is the unique feature of the t:flex® insulin pump?
How does Tandem Diabetes Care innovate in diabetes care?
